drugset / Trial / NCT04413123
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
Phase 2
Active not recruiting
60 enrolled
Bradley A. McGregor, MD
Bristol-Myers Squibb · collabExelixis · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.
Timeline
- Start
- 2020-11-05
- Primary completion
- 2026-06-20
- Completion
- 2026-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | Oral |
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |